Other biomarkers such as TMPRSS2-ERG gene fusion [16], non-coding RNA (PCA3) [17,18], and kallikrein included in basic PHI (prostate health index) or 4K tests have shown to increase sensitivity and specificity of serum PSA in prostate cancer patients. This evidence concerns the gene KLK3 and Familial prostate cancer.